Relay Therapeutics (NASDAQ:RLAY) CFO Thomas Catinazzo Sells 32,717 Shares of Company Stock

Relay Therapeutics, Inc. (NASDAQ:RLAY – Get Free Report) CFO Thomas Catinazzo sold 32,717 shares of the business’s stock in a transaction that occurred on Wednesday, November 18th. The stock was sold at an average price of $16.51, for a total value of $540,157.67. Following the transaction, the chief financial officer owned 70,948 shares in the company, valued at $1,171,351.48. The trade was a 31.56% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Thomas Catinazzo also recently made the following trade(s):

  • On Wednesday, October 28th, Thomas Catinazzo sold 1,469 shares of Relay Therapeutics stock. The stock was sold at an average price of $18.62, for a total value of $27,352.78.
  • On Tuesday, October 6th, Thomas Catinazzo sold 17,717 shares of Relay Therapeutics stock. The shares were sold at an average price of $18.59, for a total value of $329,359.03.
  • On Tuesday, September 8th, Thomas Catinazzo sold 17,717 shares of Relay Therapeutics stock. The shares were sold at an average price of $18.94, for a total value of $335,559.98.

Relay Therapeutics Stock Up 1.3%

Shares of Relay Therapeutics stock traded up $0.20 during trading on Friday, reaching $16.11. The company’s stock had a trading volume of 3,974,822 shares, compared to its average volume of 3,111,643. The business has a 50 day moving average price of $18.18 and a 200-day moving average price of $15.66. Relay Therapeutics, Inc. has a 12-month low of $6.28 and a 12-month high of $21.27. The company has a market capitalization of $3.56 billion, a P/E ratio of -10.67 and a beta of 1.74.

Relay Therapeutics (NASDAQ:RLAY – Get Free Report) last released its quarterly earnings data on Wednesday, November 4th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.40) by $0.03. Research analysts predict that Relay Therapeutics, Inc. will post -1.58 EPS for the current fiscal year.

Hedge Funds Weigh In On Relay Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. BlackRock Inc. purchased a new stake in shares of Relay Therapeutics in the second quarter valued at about $286,042,000. Perceptive Advisors LLC increased its stake in shares of Relay Therapeutics by 412.3% during the 1st quarter. Perceptive Advisors LLC now owns 9,751,141 shares of the company’s stock worth $97,024,000 after purchasing an additional 7,847,896 shares in the last quarter. Spruce Street Capital LP acquired a new position in shares of Relay Therapeutics during the 2nd quarter worth approximately $55,832,979. Bank of America Corp DE acquired a new position in shares of Relay Therapeutics during the 2nd quarter worth approximately $50,425,000. Finally, Dimensional Fund Advisors LP lifted its stake in Relay Therapeutics by 18.6% in the 1st quarter. Dimensional Fund Advisors LP now owns 2,940,536 shares of the company’s stock valued at $29,248,000 after buying an additional 460,186 shares in the last quarter. Institutional investors and hedge funds own 96.98% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently commented on RLAY shares. JPMorgan Chase & Co. raised their price objective on shares of Relay Therapeutics from $28.00 to $31.00 and gave the company an “overweight” rating in a research note on Friday, August 14th. Zacks Research upgraded shares of Relay Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Thursday, August 20th. Barclays lifted their price objective on Relay Therapeutics from $27.00 to $30.00 and gave the stock an “overweight” rating in a report on Friday, August 7th. Wall Street Zen upgraded Relay Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 7th. Finally, Citizens Jmp upped their target price on Relay Therapeutics from $21.00 to $26.00 and gave the company a “market outperform” rating in a report on Monday, August 10th. One analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Relay Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $27.00.

Check Out Our Latest Research Report on Relay Therapeutics

About Relay Therapeutics

(Get Free Report)

Relay Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing medicines for patients with serious diseases, with an emphasis on cancer. The company uses its computational drug discovery platform to study how proteins move and interact, aiming to identify drug targets and design therapies against them. Relay’s research combines experimental biology, structural biology and computational methods. Its drug development programs have included candidates targeting cancer-related pathways, such as FGFR2 and PI3K?.

Read More

Insider Buying and Selling by Quarter for Relay Therapeutics (NASDAQ:RLAY)

Receive News & Ratings for Relay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Relay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.